TRKing sarcomas for precision medicine: Seek, and ye shall find!

Abstract

Plain language summary The way in which we treat different types of cancer has changed a lot because of genome‐driven precision oncology. This approach uses information from a person’s genes to personalize their treatment. A recent study conducted by Kummar and colleagues confirms that neurotrophic receptor tyrosine kinase (NTRK) inhibitors are beneficial in treating sarcomas with NTRK fusions. This study adds to the growing evidence that genomics, which is the study of genes and their functions, can help us to identify effective treatments even for rare targets such as NTRK fusions. This emphasizes the importance of using advanced DNA sequencing techniques in analyzing the genetic makeup of all sarcomas.